98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA

Saved in:
Bibliographic Details
Published inJournal of thoracic oncology Vol. 16; no. 4; pp. S750 - S751
Main Authors Paz-Ares, L., Ciuleanu, T-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., Alexandru, A., Sakai, H., Scherpereel, A., Reck, M., Lu, S., John, T., Meadows-Shropshire, S., Balli, D., Agrawal, S., Carbone, D.P.
Format Journal Article
LanguageEnglish
Published Elsevier Inc 01.04.2021
Online AccessGet full text

Cover

More Information
ISSN:1556-0864
1556-1380
DOI:10.1016/S1556-0864(21)01940-7